Abstract
Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burki, H. R., Asper, H., Ruch, W., Zuger, P. E.: Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF 25-397 and 29-712: Effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology 57, 227–237 (1978)
Calne, D. B.: Developments in the pharmacology and therapeutics of parkinsonism. Ann. Neurol. 1, 111–119 (1976)
Carlsson, H.: Some aspects of dopamine in the basal ganglia. In: Basal ganglia, M. O. Yahr, ed., pp. 181–190. New York: Raven 1975
Corrodi, H., Fuxe, K., Hökfelt, T., Lindbrink, P., Ungerstedt, U.: Effects of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409–412 (1973)
Corsini, G. U., Del Zompo, M., Menconi, S., Cianchetti, C., Mangoni, A., Gessa, G. L.: Sedative, hypnotic and antipsychotic effect of low dose apomorphine in man. Adv. Biochem. Psychopharmacol. 16, 645–648 (1977)
Creese, I., Snyder, S.: Characterization of DA binding sites in striatum. In: Catecholamines: Basic and clinical frontiers, E. Usdin, I. Kopin, J. Barchas, eds. New York: Pergamon (in press) 1979
Fuxe, K., Corrodi, H., Hökfelt, T., Lindbrink, P., Ungerstedt, U.: Ergocornine and 2-Br-α-ergocryptine: Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52, 121–132 (1974)
Fuxe, K., Fredholm, B. B., Ogren, S.-O., Agnati, L. F., Hökfelt, T., Gustafsson, J.-A.: Ergot drugs and central monoaminergic mechanisms: A histochemical, biochemical and behavioral analysis. Fed. Proc. 37, 2181–2191 (1978)
Goldstein, M., Lew, J. Y., Nakamura, S., Battista, A. F., Lieverman, A., Fuxe, K.: Dopaminephilic properties of ergot alkaloids. Fed. Proc. 37, 2202–2206 (1978)
Jaton, A. L., Loew, D. M., Vigouret, J. M.: Proceedings: CF 25-397 (9,10-didehydro-6-methyl-8-beta-(2-pyridylthromethyl) ergoline), a new central dopamine receptor agonist. Br. J. Pharmacol. 56, 371 (1976)
Kebabian, J. W., Kebabian, P. R.: Lergotrile and lisuride; in vivo dopaminergic agonists which do not stimulate the presynaptic autoreceptor. Life Sci. 23, 2199–2204 (1978a)
Kebabian, J. W.: Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitivity adenylyl cyclase. Life Sci. 23, 479–484 (1978b)
Kehr, W., Carlsson, A., Lindqvist, M.: Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity, J. Pharm. Pharmacol. 24, 744–747 (1972)
Langer, S. Z.: Presynaptic receptors and the regulation of transmitter release in the peripheral and central nervous system: Physiological and pharmacological significance. In: Catecholamines: Basic and clinical frontiers, E. Usdin, I. Kopin, J. Barchas, eds. New York: Pergamon 1979) (in press)
Muller, E. E., Panerai, A. E., Coechi, P., Mantegazza, P.: Endocrine profile of ergot alkaloids. Life Sci. 21, 1545–1558 (1977)
Silbergeld, E. K., Hruska, R. E., Weir, R., Kennedy, S.: Dopaminergic and serotonergig effects of ergot drugs. In: Ergot derivatives in motor and cognitive disorders, K. Fuxe, D. B. Calne, eds. London: Pergamon 1979 (in press)
Small, J. C., Kellams, J. J., Milstein, V., Klipper, M., Lemberger, L.: Effect of lergotrile on schizophrenia and drug-induced parkinsonism. Commun. Psychopharmacol. 1, 461–467 (1977)
Spitzer, R. L., Endicott, J., Robins, E.: Preliminary report of the reliability of research diagnostic criteria (RDC) applied to psychiatric case records. In: Prediction in psychopharmacology: Preclinical and clinical correlates, A. Sudilovsky, S. Gershon, R. Deer, eds., pp. 231–245. New York: Raven 1975
Tamminga, C. A., Schaffer, M. H., Smith, R. C., Davis, J. M.: Schizophrenic symptoms improve with apomorphine. Science 200, 567–568 (1978)
Tamminga, C. A., Chase, T. N.: Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Arch. Neurol. (in press 1979)
Teychenne, P. F., Pfeiffer, R., Bern, S. M., Calne, D. B.: Experiences with a new ergoline (CF 25-397) in parkinsonism. Neurology 27, 1140–1143 (1977)
Titeler, M., Tedesco, J. L., Seeman, P.: Selective labeling of presynaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of postsynaptic sites by 3H-neuroleptics. Life Sci. 23, 587–592 (1978)
Trabucchi, M., Andreoli, V. M., Frattola, L., Spano, P. F.: Pre- and postsynaptic action of bromocriptine: Its pharmacologic effect in schizophrenia and neurologic disease. Adv. Biochem. Psychopharmacol. 16, 661–665 (1977)
Trabucchi, M., Spano, P. F., Tonon, G. C., Frattola, L.: Effects of bromocriptine on central dopaminergic receptors. Life Sci. 19, 225–232 (1976)
Walters, J. R., Roth, R. H.: Dopaminergic neurons: Drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. J. Pharmacol. Exp. Ther. 191, 82–91 (1974)
Walters, J. R., Baring, M. D., Lakoski, J. M.: Effects of ergolines on dopaminergic and serotonergic single unit activity. In: Ergot derivatives in motor and cognitive disorders, K. Fuxe, D. B. Calne, eds. London: Pergamon 1979a, in press
Walters, J. R., Baring, M. D., Lakoski, J. M.: Effects of dopamine agonists on dopaminergic unit activity. In: Catecholamines: Basic and clinical frontiers, E. Usdin, I. Kopin, J. Barchas, eds. New York: Pergamon 1979b, in press
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tamminga, C.A., Schaffer, M.H. Treatment of schizophrenia with ergot derivatives. Psychopharmacology 66, 239–242 (1979). https://doi.org/10.1007/BF00428312
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00428312